Ascendis Pharma enters its Q1 2026 earnings call — scheduled for tomorrow, May 7 — with its ORTEX short score having nearly doubled over the past two weeks, setting up one of the more charged pre-earnings positioning pictures in the biotech space this week.
The short score is the clearest signal in the data right now. It has jumped from 40.3 on April 22 to 58.8 today — a 46% rise in just under two weeks — putting it in territory that reflects meaningfully elevated short-side interest even if the absolute short interest level itself is modest. Availability of shares to borrow sits at around 269% of estimated short interest, which is tight-to-normal for a large-cap biotech, meaning the lending market is not under stress despite the shift in sentiment. Cost to borrow has edged up from 0.51% on April 22 to 0.98% today — a 33% move over the week — but remains low in absolute terms, consistent with a stock that is not being squeezed or difficult to borrow. The overall borrow picture is comfortable; the rising short score reflects a change in direction, not a crowded trade.
Options lean emphatically bullish. The put/call ratio has dropped to 0.32 today — the lowest reading of the past year — reversing from 0.39 at the start of last week. Call buyers dominate the options market heading into the print, with significantly more upside positioning than downside hedging. That directional skew stands in contrast to the rising short score, making the setup a genuine tug-of-war between call buyers and an expanding short base. The stock closed at $225.28 on Tuesday, down 1.5% on the day but up 1.4% on the week, trading at 43x trailing earnings and 19.6x EV/EBITDA — the latter down 2.2 turns over 30 days, suggesting the market has trimmed growth expectations modestly heading into the report.
Analysts remain constructive. The consensus is a buy, with the mean price target implying roughly 32% upside to current levels at around $254. Analyst sentiment has been stable rather than active — no major rating changes in the snapshot — with two buy recommendations and no sells on record as of late April. The bull case centres on the TransCon technology platform and the commercial ramp of Yorvipath, the company's product for adult growth hormone deficiency. Published data released late Wednesday from the ApproaCH trial added a fresh catalyst: an expanded subgroup analysis showing children with achondroplasia treated with TransCon CNP (navepegritide) achieved greater annual growth velocity versus placebo. The bear case is narrower but real: clinical execution risk, competition from other endocrine-focused biopharmas, and longer-term pricing pressure in a market that is increasingly scrutinising specialty drug economics. The forward EPS growth trajectory ranks in the 85th percentile of the universe — a strong number for a company still working through its path to sustained profitability. Full-year 2025 sales came in at €720 million, nearly double the prior year's €364 million, with net loss narrowing sharply to €228 million from €378 million — a commercialisation inflection that the Street has not fully re-rated.
On the institutional side, First Trust Advisors added 17,156 shares in April, while BlackRock added 4,254 — both reporting as of April 30. Invesco trimmed modestly. Schroder cut its position by 7,273 shares as of January, the largest reduction in the disclosed holder list. The net picture is mild accumulation from passive and rules-based managers into the earnings event, without any large active manager making an aggressive directional call.
Tomorrow's Q1 print is therefore less about whether Ascendis is growing — the revenue trajectory is established — and more about whether Yorvipath's commercial uptake is tracking to full-year guidance, and whether the ApproaCH data drop ahead of earnings proves to be deliberate pre-release positioning or simply a scheduled conference readout.
See the live data behind this article on ORTEX.
Open ASND on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
